Type I interferons (IFN-I) are the principal antiviral molecules of the innate immune system and can be made by most cell types, including central nervous system cells. IFN-I has been implicated in neuroinflammation during neurodegeneration, but its mechanism of induction and its consequences remain unclear. In the current study, we assessed expression of IFN-I in murine prion disease ( 
some degree, during bacterial infection. In the context of viral infection, they are typically induced via engagement of TLR3, TLR7, or other pattern recognition receptors (PRRs) such as RIG-1 and MDA-5 that recognize intracellular single-stranded or double-stranded RNA (Hoffmann, Schneider, & Rice, 2015) . IFN-I is also induced via cytosolic DNA sensing pathways that signal via endoplasmic adaptor molecule stimulator of interferon genes (STING) (Gurtler & Bowie, 2013) . First identified by expression cloning, STING was shown to activate both NF-κB and IRF3 transcription pathways to induce expression of IFN-I and exert a potent antiviral state following expression (Ishikawa, Ma, & Barber, 2009 ).
The principal cells responsible for IFN-I production during systemic viral infection include macrophages and plasmacytoid dendritic cells, but it is clear that most cell types in the central nervous system (CNS) can mount IFN-I responses (Blank et al., 2016; Owens, Khorooshi, Wlodarczyk, & Asgari, 2014) . These responses may arise in response to systemic viral infection, circulating IFNα, or viral mimetics such as poly inosinic: poly cytidylic acid Wang, Campbell, & Zhang, 2008) or in response to brain injury and neurodegeneration (Field, Campion, Warren, Murray, & Cunningham, 2010; Hosmane et al., 2012; Khorooshi & Owens, 2010; Main et al., 2016; Minter et al., 2016; Wang, Yang, & Zhang, 2011) . Recently, both astrocytes and microglia have been shown to express a number of DNA sensors and to respond to DNA stimulation with robust IFN-I responses (Cox et al., 2015) .
There is evidence for both protective and deleterious roles of IFN-I in different disease states (Owens et al., 2014) . The predominant view of IFN-I in the brain is that they are anti-inflammatory. IFN-I induce the anti-inflammatory cytokine IL-10 ( Lin et al., 2013) and in this way may inhibit IL-1 production (Guarda et al., 2011) . Consistent with this, in a CNS context, IFN-β is a first-line therapy for multiple sclerosis and limits lymphocyte infiltration into the brain and therefore also decreases relapse rate (Owens et al., 2014; Prinz et al., 2008) .
Moreover, axonal degeneration in the perforant path has been shown to induce a robust type I interferon response, which appears to limit CCL2 and MMP9 expression and prevent exaggerated cell infiltration in the injured area (Khorooshi & Owens, 2010) . Similarly, an in vitro model of axon injury showed IFN-I induction in microglia. Blocking this response via disruption of Toll/interleukin-1 receptor domaincontaining adapter inducing interferon-β (TRIF), impaired microglial clearance of axonal debris, and inhibited axon outgrowth after dorsal root axotomy (Hosmane et al., 2012) . Conversely, detrimental actions have also been ascribed to IFN-I. Transgenic overexpression of IFN-α in the brains of mice is associated with increased inflammation and neurodegeneration (Akwa et al., 1998; Campbell et al., 1999) . IFNβ has been shown to be elevated with age and direct administration of antibodies against IFNAR1 protected against age-dependent cognitive impairment and increased neurogenesis in the sub-ventricular zone (Baruch et al., 2014) .
All type I IFNs can signal via the heterodimeric interferon α/β receptor (IFNAR), which classically signals via a JAK/STAT pathway leading to the upregulation of IFN-stimulated genes (ISGs) (Schoggins & Rice, 2011) , and generation of IFNAR1-deficient mice (Hwang et al., 1995) has facilitated attempts to understand the role of IFN-I in neurodegenerative disease. With respect to chronic neurodegenerative processes, IFNAR1 deficiency resulted in modestly slowed disease progression in SOD1(G93A) model of amyotrophic lateral sclerosis (Wang et al., 2011) and reduced dopaminergic cell death in the MPTP model of Parkinson's disease (Main et al., 2016) .
Conversely, loss of dopaminergic neurons was observed in IFNβ
−/− mice (Ejlerskov et al., 2015) . Both human Alzheimer's disease (AD) and in vitro and in vivo models of AD show increased IFN-I expression (Mesquita et al., 2015; Taylor et al., 2014) , and in vivo studies showed decreased pathology and altered microglial phenotype in IFNAR1 −/− × APP SWE /PS1 ΔE9 mice (Minter et al., 2016) . Whether effects on microglia were secondary to effects on Aβ is unclear.
Therefore, IFN-I have divergent roles in the degenerating brain, but cellular sources and mechanisms of induction as well as downstream functions remain incompletely understood. Here, we characterized the IFN-I response in the degenerating brain in the ME7 model of prion disease and then studied both its pathway of induction and the impacts of this IFN-I response on microglial activity and on progression of neurodegeneration. We reveal a STING-mediated IFN-I response that significantly alters microglial phenotype and disease progression.
| MATERIALS AND METHODS
Female C57BL/6 (Harlan, Bicester, UK) were housed in groups of five and given access to food and water ad libitum. IFNAR1 −/− mice on a C57BL/6 background were kindly provided by Professor Paul Hertzog (Monash University, Clayton, Australia). Generation of mutant mice was as previously described (Hwang et al., 1995) : 129Sv ES cells were transferred into the Balb/C background and offspring backcrossed onto a C57BL6/J background for more than seven generations.
Females were used to avoid fighting and injury, which has significant effects on behavior. Tmem173 <tm1Camb> (STING −/− ) mice, on a C57BL/6 (Charles Rivers) background, were initially provided by Dr. Jin Lei (University of Florida), and generation of STING −/− mice is as described (Jin et al., 2011) , and these mice were then maintained as a homozygous colony in the TCD comparative medicine unit. 
| Surgery and animal treatments
Mice were weighed, anesthetized intraperitoneally (i.p.) with 1.2%
Avertin (2,2,2-tribromoethanol solution; 0.2 mL/10 g body weight) and positioned in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). The incisor bar was set at −1 mm, to give an approximately level head. The scalp was incised, and the skull exposed. Two small holes were drilled in the skull either side of the midline to allow for bilateral injection of 1 μL of a 10% w/v scrapie (ME7 strain)-infected C57BL/6 brain homogenate made in sterile phosphate-buffered saline (PBS).
Injections were made into the dorsal hippocampus (coordinates from bregma: anteroposterior, −2.0 mm; lateral, ±1.6 mm; depth, −1.7 mm) using a 10 μL Hamilton microsyringe (Hamilton, Reno, NV) with a 26 gauge needle. Control animals were injected with a 10% w/v normal brain homogenate (NBH) in PBS, derived from a naïve C57BL/6 mouse.
Following intrahippocampal injection, the needle was left in place for 2 min before being withdrawn slowly to minimize reflux. Mice were then placed in a heated recovery chamber and finally re-housed.
Sucrose (5% w/v) and carprofen (0.05% v/v; Rimadyl, Pfizer, Ireland) were added to drinking water for 2 days following surgery to provide post-surgical analgesia and to optimize post-surgical recovery. One group of ME7 animals were treated with SC-560 (30 mg/kg in 24% DMSO) to assess which isoform of cyclooxygenase (COX) was responsible for prostaglandin E2 synthesis. Animals were euthanized at preplanned time points based on prior publications of neuropathology, except in survival experiments. In those experiments, due to regulatory authority licensing restrictions, animals were euthanized when they reached a predetermined humane endpoint of 15% loss of peak body weight in conjunction with overt clinical signs/terminal symptoms:
kyphosis, incontinence, hunched posture, and ruffled fur.
| Behavioral and motor coordination testing
For all behavioral experiments, mice were moved from their homeroom and left in the test room for 15 min before beginning the task to ensure that they were in an optimal state of arousal.
| Open field
The open field arena consisted of a plastic base (58 cm × 33 cm) surrounded by walls of 19 cm. The floor of the box is divided into a grid of equal sized squares. Measurement was made of distance traveled (in terms of grid squares crossed) and total number of rears.
Weekly measurements of open field activity were recorded for 3 min from when animals were placed facing any corner of the arena.
| Burrowing
Black plastic burrowing tubes, 20 cm long, 6.8 cm diameter, sealed at one end were filled with 300 g of normal mouse diet food pellets, and placed in individual mouse cages. The open end was raised by 3 cm above the floor by a wooden support to prevent nonpurposeful displacement of the contents. Mice were placed individually in the cages for 2 hr, at which point the food remaining in the cages was weighed and the amount displaced (burrowed) was calculated. Weekly measurements were taken during prion disease progression.
| Horizontal bar
The horizontal bar was designed to assess forelimb muscular strength and coordination. It consisted of a 26 cm long metal bar, 0.2 cm diameter, supported by a 19.5 cm high wooden column at each end. Each mouse was held by the tail and allowed to grip the central point of the bar with its front paws only. The tail was rapidly released, and mice were scored based on whether they fell, held on for 60 s, or reached a platform on a supporting column, with the latter two results scoring the maximum of 60 s.
| Inverted screen
The inverted screen assessed muscular strength for all four limbs. It consisted of a wooden frame, 43 cm square, covered with wire mesh (12 mm squares of 1 mm diameter wire). The mouse was placed on the screen, which was then slowly (2 s) inverted. The time it took for the mouse to fall was measured, up to a criterion of 60 s. Padding was provided to cushion mice falling from both bar and screen apparatus. 2.4 | Fluorescence-activated cell sorting (FACS) of microglia and astrocytes
| Tissue collection

| Enzymatic digestion and myelin removal
The area encompassing the dorsal hippocampus and thalamus (area of maximum pathology in ME7) was punched from thick coronal sections at the appropriate rostro-caudal position and kept in ice cold 1 mL HBSS. This tissue punch was minced and dissociated in 5 mL of enzyme mixture containing collagenase (2 mg/mL), DNase I (28 U/mL), 5% FBS, and10 μM HEPES in HBSS, followed by a filtering step using a 70-μm cell strainer (BD Falcon) to achieve a single-cell suspension. Myelin from single-cell suspension obtained was removed by subsequently incubating with Myelin Removal Beads II for 20 min and passing through LS columns mounted over QuadroMACS magnet.
| Staining and cell sorting
The myelin-depleted single-cell suspension obtained above was incubated (15 min on ice) with anti-mouse CD16/CD32 antibody to block Fc receptors and subsequently incubated with anti-CD11b PEcy7 designed to cross an intron such that they were cDNA specific. In some cases, the fluorescent DNA binding probe SYBR green has been used in place of a specific probe. Primer and probe sequences, along with accession numbers for mRNA sequence of interest may be found in Table 1 . Oligonucleotide primers were resuspended in 1× TE buffer (Tris Base 10 mM, EDTA 1 mM; pH 7.5-8.0) and diluted to 10 μM working aliquots. All primer pairs were checked for specificity by standard reverse transcription (RT)-PCR followed by gel electrophoresis, and each primer pair produced a discrete band of the expected amplicon size. Table 1 lists the sequences for primers and probes for those assays that have not been published in our prior studies (Cox et al., 2015; Cunningham, Campion, Teeling, Felton, & Perry, 2007; Field et al., 2010; Hughes, Field, Perry, Murray, & Cunningham, 2010; Palin, Cunningham, Forse, Perry, & Platt, 2008 primers and probe, 4.0 μL RNase-free water. Where SYBR green was used, RNase-free water was substituted in place of the probe. To this, 1 μL of cDNA was added to give a final reaction volume of 14 μL.
Samples were run in the 7300 Real-Time and QuantStudio 5 RealTime PCR System (Applied Biosystems, Warrington, UK) under standard cycling conditions: 95 C for 10 min followed by 95 C for 10 s and 60 C for 30 s for 45 cycles. A standard curve was constructed from serial one in four dilutions of the cDNA synthesized from total RNA isolated from mouse brain tissue 24 hr after intra-cerebral challenge with 2.5 μg LPS, which is known to upregulate most target transcripts of interest in this study. A standard curve was plotted of C t value versus the log of the concentration (assigned an arbitrary value since the absolute concentration of cytokine transcripts is not known).
All PCR data were normalized to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
| Western blotting
WT and IFNAR1 −/− mice inoculated with NBH or prion disease (ME7)
were perfused with sterile saline. Tissue punches containing dorsal hippocampus and posterior thalamus weighing 20-30 mg were homogenized in 100 μL of lysis buffer which contained 50 mM TrisHCl, 150 mM NaCl, 1% Triton ×100, and protease and phosphatase inhibitors (Roche). A DC protein Assay (Biorad) was carried out, and samples were equalised to 8 mg protein/mL. Typically, 40 μg of protein were run on 10% SDS-PAGE gels after boiling at 90 C for 5 min in sample buffer containing Tris-HCl, glycerol, 10% SDS, β-mercaptoethanol, and bromophenol blue. Of note, 5 μL of molecular weight markers (Santa Cruz: SC-2361/Sigma: P-1677) were also loaded onto the gel. Gels were run at 60 mA for 1 hr and transferred onto PVDF membrane at 225 mA for 90 min. Membranes were then blocked in 5% milk or BSA in TBS-T for 2 hr at room temperature. Table 2 lists the antibodies and dilution and incubation times.
All blots except those for PrP used the above protocol. Blotting was carried out, and samples were equalized to 10 mg/mL. The equalized cerebellar homogenate was then diluted 1:5 into PBS with protease inhibitors ± proteinase K (1,000 μg/mL). Proteinase K treatment was used to determine protease resistance of PrP Sc . Samples containing proteinase K were then incubated at 37 C for 45 min. Samples were boiled in sample buffer at 90 C for 5 min and then spun at 20,800 g for 5 min. Of note, 10% SDS-PAGE gels were loaded with 10 μg total protein and run at 60 mA. Membranes for PrP blots were incubated in 5% BSA in PBS-T for 1 hr at room temperature before probing with the primary antibody. After incubation with the primary and secondary antibodies, all membranes were then exposed for various times using Supersignal West Dura Extended Duration ECL (Pierce). The blots were quantified using Image J software. 
| General immunohistochemistry protocol
Immunohistochemistry was performed for microglia (IBA-1), synapto-
Sections were dewaxed in xylene for 15 min followed by histoclear and then rehydrated through a series of ethanols of decreasing concentration: 100% II, 100% I, 95%, 85%, 70%. Following rehydration, nonspecific endogenous peroxidase activity was eliminated (quenched) by incubating sections in 1% v/v hydrogen peroxide in methanol (1 mL 30% H 2 O 2 per 100 mL methanol). For most immunohistochemical reactions, antigen retrieval was performed by incubation in citrate buffer, pH 6, and microwaving twice for 5 min followed by 5 min of cooling after incubation (temperature of >80% for ≥15 min). Slides were cooled to room temperature by gently rinsing with cold tap water. Sections were washed three times in PBS for 5 min, encircled with a ring of wax using a liquid blocking PAP pen (Sigma, Poole, UK), and the appropriate blocking serum applied (40 μL) and incubated at room temperature for 30 min before application of primary antibody overnight, thorough washing and application of biotinylated secondary antibody for 45 min. The reaction was completed using the ABC method with peroxidase as enzyme, diaminobenzidine as chromagen, and 0.05% v/v hydrogen peroxide as substrate. All biotinylated secondary antibodies and ABC kits were supplied by Vector Laboratories (Peterborough, UK). Slides were counterstained with hematoxylin, dehydrated, and coverslips mounted using DPX (Sigma, Poole, UK), except those for NeuN and Sy38 (to preserve high contrast for quantification).
| Exceptions to the general protocol
PrP Sc
After dewaxing and rehydration, slides were placed in a container of distilled water and autoclaved at 121 C for 20 min. Following a brief PBS wash, the slides were placed in 90% formic acid for 5 min.
Following further PBS washes, the slides were quenched in 1% H 2 O 2 for 15 min and then incubated with Proteinase K and distilled water for 30 min. These steps were taken to ensure that the PrP antibody only stained for protease-resistant PrP Sc . Thereafter, the reaction continued as above.
Synaptophysin
After rehydration, sections were treated with 0.2 M boric acid (pH 9) at 65 C for 30 min and cooled to room temperature thereafter.
The DAB reaction had the additional component of 0.15 g ammonium nickel sulfate in the DAB solution to enhance intensity.
| Quantification of synaptophysin and NeuN
Synaptophysin density was assessed using transmittance of synaptic layers assessed in ImageJ after image capture using a Leica DM3000 microscope and CellA software (Olympus). A mean transmittance was calculated for corpus callosum (cc), overlying cortex, stratum oriens, CA1, stratum radiatum, and the stratum lacunosum. The relatively unstained corpus callosum (cc) served as an internal control, and synaptophysin density was calculated according to the formula: cc − rad/cc − cortex.
Synaptophysin density was measured in two thalamic areas in the same sections: the ventral posteromedial nucleus of the thalamus (VPM) and the posterior nucleus of the thalamus (Po). Synaptophysin density in the thalamus was calculated according to the formula: cc − VPM/cc − Po. Once again, the cc served as an internal control.
For NeuN quantification in ImageJ, the free-hand tool was used to draw around the Posterior thalamus, which shows the greatest neuronal loss in the ME7 model (Reis, Hennessy, Murray, Griffin, & Cunningham, 2015) . Within this region, the number of cells positive for NeuN-labeling were individually counted using a hand-held click counter and divided by the unit area in the selected region. An average of this measure was taken from each animal and collated to form a group average, which represented the extent of neuronal loss in the posterior nucleus.
2.7.6 | Sectioning of fresh frozen tissue and CD68 labeling v/v Decon detergent in distilled water for 30-60 min, followed by a rinse under cold tap water for several minutes. Slides were rinsed twice in distilled water and then dried in an oven at 60 C overnight.
Slides were coated with APS by immersion in a 2% v/v solution of APS in methanol for 10 to 15 s. Finally, slides were rinsed in methanol followed by distilled water and dried overnight at 37 C.
Slides were air dried for 1 hr after removal from the −20 C freezer, fixed in absolute alcohol at 4 C and washed in 0.1 M PBS before blocking in 10% normal rabbit serum. Primary antibody against CD68 (FA11) was applied at 1/100 for 1 hr. Thereafter, the reaction was continued as per the general protocol. For each section (2-4 sections/animal, −1.86 to −2.3 mm from Bregma), the cc was acquired using a ×20 objective lens in optical microscope (Leica DM3000)
coupled with a digital camera (Olympus) and Cell A software. CD68 + -stained area fraction quantification was performed using ImageJ 1.49v
Software (NIH) after creating binary images and set at 144 (area 1) and 146 (area 2) upper average threshold. CD68 + positive cells were counted using particle analyzer with pixel size = 280-Infinity and 3 | RESULTS
| IFN-I in chronic neurodegeneration (ME7 prion disease)
We 
| Impact of IFN-I on cellular and molecular aspects of prion disease
Along with Irf7 and Mx1, Eif2ak2 (PKR) is a classical IFN-dependent gene known to be induced by IFN-I. Here, we demonstrate the induction of all three genes in the ME7 brain and show that this induction is absent in IFNAR1 −/− mice inoculated with ME7 (Figure 3a) .
The Eif2ak2 gene product PKR has been shown to be capable of phosphorylation of eukaryotic initiation factor 2α (eIF2α), a translational controller which has been proposed to play a key role in the progression of neurodegeneration in models of prion disease (Moreno et al., 2012; Moreno et al., 2013) . We thus assessed the expression levels of PKR and eIF2α. Western blotting showed a very robust increase in the expression of PKR protein in ME7 animals with respect to NBH animals, and this increase was abolished in IFNAR1 −/− mice (Figure 3b,c) . Therefore, the ME7-associated increase in PKR is IFN-I mediated. However, contrary to previous findings, we did not detect any change in the phosphorylation status of eIF2α in prion disease, when expressed as a ratio to total eIF2α (Figure 3b,c,d ).
| Impact of IFN-I on microglial transcriptional profile
Given recent findings about the effects of IFN-I expression on the inflammatory profile of cells in the CNS, we performed immunohistochemistry for the microglial marker IBA1 and an analysis of transcription of a large number of genes known to be associated with microglial activation in ME7 animals (Hughes et al., 2010) . We Table 4 . Il1b and, to a lesser extent, Nos2 (iNOS) were modestly increased by disease but not affected by genotype (Figure 4a ,e), whereas Tnf (4b), and Tgfb1 (4c) were robustly induced in disease but suppressed in IFNAR1 −/− mice. Il10 (4d) and Trem2 (4g) were clearly elevated by disease, and this expression was reduced in IFNAR1 −/− mice. Arg1 was neither altered by disease nor by genotype (4f ). There is, however, clear evidence of a shift in phagocytic and lysosomal activation: the complement pathway components C1qα (4i), C3 (4j) and the complement receptor subunit Itgam (CD11b) (4k) were all significantly elevated in disease, and this effect was largely reversed in IFNAR1 −/− mice. The same pattern was also observed for transcripts for scavenger receptors (SR) Cd68 (4h) and
Msr1 (SRA2) (4l), the NADPH oxidase components Cybb (gp91) (4m),
and Cyba (p22) (4n) and for the lysosomal proteases Ctss (cathepsin S, 4o) and Ctsd (cathepsin D, 4p).
These data are strongly suggestive of an altered microglial phenotype; but, because some of these transcripts may also be astrocytic in origin, we then isolated microglia and astrocytes from additional animals and assessed key markers ( Figure 5 ). The microglial markers
Cd68, Itgax, Tmem119, and Trem2 all showed significant disease-associated increases (p < 0.01), and those for Itgax, Tmem119, and respectively Eif2ak2 (PKR) in FACS-sorted microglia and astrocytes from ME7 and NBH animals at 19 weeks postinoculation. Significant differences by Student's t-test are denoted *p < 0.05, **p < 0.01, and ***p < 0.001. Data are expressed as mean ± SEM; n = 3 for NBH, n = 5 for ME7 for homogenates and n = 6 for NBH, n = 7 ME7 for FACS-sorted samples exclusively in microglia, which is suppressed in IFNAR1 −/− mice, was observed for complement components (C3, C1q) and the lysosomal cathepsin D (significant interaction of genotype and disease [F ≥ 10.06, df 1,21, p ≤ 0.0048], indicating disease-associated increases that were absent in IFNAR1 −/− mice). C3 and C1qα expression was evident in astrocytes but was not significantly affected by disease. In addition, transcripts for cathepsin S and NADPH oxidase subunits (Cyba, Cybb) showed disease-associated increases in microglia (significant interaction between disease and genotype: F ≤ 13.87, df 1,21, p ≤ 0.0024) which were once again IFNAR1-dependent.
Cathepsin S and the NADPH oxidase subunits also showed increases in astrocytes, but the overall level of expression of these genes in astrocytes was much lower than in microglia. Therefore, at the transcriptional level, it is clear that the lack of IFNAR1 signaling results in significant phenotypic changes in microglia and astrocytes.
| STING-mediated IFN-I production
Given the influence of IFNAR1 on microglial phenotype, we interro- (b) Expression of PKR and activation of eIF2α. Example western blots show two samples each of normal brain homogenate (NBH) (in WT mice), ME7 (WT), NBH (in IFNAR1 −/− mice), and ME7 (IFNAR1 −/− ) and blotted with antibodies against PKR, phospho-eIF2α and total eIF2α (exemplars for groups of n = 8). Bands were quantified by densitometry, normalized to the equivalent sample for total eIF2α, and then expressed as a fold increase from NBH (WT). ** denotes a significant interaction between disease status and strain, for PKR expression, by two-way ANOVA (F = 11.67, df 1,28; p = 0.002) ) and analyzed by two-way ANOVA with disease and strain as between subjects factors. Significant differences are denoted *p < 0.05, **p < 0.01, and ***p < 0.001 by Bonferroni post hoc analysis with this, Irf7 mRNA was also significantly decreased in microglia (and in astrocytes, not shown) isolated from STING although there were no such significant differences in the thalamus, which is predominantly grey matter at this anterior-posterior location.
Based on these white matter CD68 changes, we assessed both IBA1
and cathepsin D labeling in the cc, directly dorsal to the degenerating hippocampus. We show (Figure 8m ,q) that in both cases, there is a clear increase in labeling in this white matter tract in ME7 that contains axons exiting the degenerating hippocampus. This increase is apparent in ME7
WT animals but mitigated in IFNAR1 −/− mice (Figure 8n,r) . Collectively, these data suggest that neurodegeneration-associated increases in microglial lysosomal cathepsin D activity and white matter CD68 expression is significantly mitigated in IFNAR1 −/− mice, suggesting that, in the absence of IFN-I signaling, there is less microglial phagocytic activity in areas of the brain in which degenerative processes are occurring.
| Microglial COX-1-mediated prostaglandins
We have previously shown that COX-1 expression is robustly increased in microglial cells during progression of the ME7 model of prion disease (Griffin, Skelly, Murray, & Cunningham, 2013) . Accordingly, PGE2 is also robustly increased and systemic administration of the COX-1-specific drug SC560 (30 mg/kg i.p.) completely abolished these levels, confirming synthesis by COX-1 (Figure 9a ; p < 0.001 by Bonferroni post hoc after significant one way ANOVA). The expression of mRNA for COX-1 was significantly reduced in ME7 IFNAR1 −/− mice (Figure 9b ), and consistent with this, there was also a marked reduction of PGE2 levels in ME7
IFNAR1
−/− mice with respect to wild-type ME7 animals (Figure 9c; p < 0.001 by Bonferroni post hoc after significant one-way ANOVA).
FIGURE 5 Transcriptional analysis of microglia and astrocytes isolated from normal brain homogenate (NBH) and ME7 animals on IFNAR1-deficient and wild-type backgrounds. Top panel; changes in Cd68, Itgam, Itgax, Tmem119, and Trem2 transcripts in isolated microglia. Second panel; neuroinflammatory transcripts Tgfb1, Tnfa, and Il1b in isolated microglia and astrocytes. Thereafter, panels illustrate transcript levels, from isolated microglia and astrocytes, of complement pathway components: C1q, C3, of lysosomal cathepsins Ctsd and Ctss, and of NADPH oxidase subunits Cybb and Cyba. All data are from animals at 19 weeks plotted as mean ± SEM with n = 6 (NBH in WT), n = 5 (NBH in IFNAR1 −/− ), n = 7 (ME7 in WT) and n = 7 (ME7 in IFNAR1
) and analyzed by two-way ANOVA with disease and strain as between subjects factors. Significant differences are denoted *p < 0.05, **p < 0.01, and ***p < 0.001 by Bonferroni post hoc analysis Therefore, IFN-I influences the microglial expression and action of COX-1, thus contributing to brain PGE2 levels.
| Effect of IFNAR1 deficiency on disease progression
We examined previously characterized measures of disease progression to assess the impact of IFNAR1 −/− on progression of this fatal neurodegenerative disease. Because all measures were known effects of ME7 (Betmouni, Deacon, Rawlins, & Perry, 1999; Cunningham et al., 2005; Reis et al., 2015) , we have included NBH controls for comparison only and statistical analysis has been performed only on WT and IFNAR1 −/− ME7 animals.
| Presynaptic terminals
Synaptophysin labeling at 19 weeks postinoculation demonstrated robust density and intact layering of presynaptic terminals in the hippocampus and high density of terminals in the ventroposterior (VP) and posterior (Po) thalamic nuclei (Figure 10a ; white line divides VP and Po). Both the hippocampus and the thalamus showed severe synaptic loss in ME7 animals as previously shown (Reis et al., 2015) , and this was particularly apparent as a decrease in the ratio between synaptic density in VP and Po. Although synaptic loss was clearly present in IFNAR1 −/− ME7 animals, this was significantly less than that apparent in WT ME7 animals. This difference in synaptic loss was statistically significant (p < 0.05 by Student's t-test) and is shown in Figure 10b .
Similarly, we have previously described significant neuronal loss in the posterior thalamic nucleus (Reis et al., 2015) . The extent of neu- animals inoculated with normal brain homogenate (NBH) and ME7. Top panel; transcripts of IFN-I response, Ifnb1, Irf7, and Eif2ak2 (PKR) in isolated microglia. Bottom panel; transcripts of Tgfb1, C1q, C3, and Ctsd in isolated microglia. All data are plotted, from animals at 20 weeks postinoculation, as mean ± SEM (n = 6 NBH in WT, n = 3 NBH in STING −/− , n = 7 ME7 in WT, n = 6 ME7 in STING −/− ) and analyzed by twoway ANOVA with disease and strain as between subjects factors. Significant differences in pairwise comparisons by Bonferroni post hoc analysis, after significant main effects, are denoted *p < 0.05, **p < 0.01, and ***p < 0.001 compared to wild-type prion diseased mice (Figure 10g ). Animals were euthanized based on reaching a humane endpoint of loss of 15% of peak body weight. Survival was calculated as days postinoculation, and
Kaplan-Meier log-rank survival analysis revealed that ME7-inoculated IFNAR1 −/− mice survived on average 2 weeks longer than their wild-type counterparts (median survival 162 days vs 148 days; p < 0.0001).
STING −/− mice were also protected against development of late stage signs (Supplementary Information S3) . Thus, the absence of IFNAR1 and consequent loss of signaling of the IFN-I confers a delay not just in survival time but also in the onset of neurological dysfunction
(by approximately 2 weeks) in prion-diseased animals.
| Prion protein aggregation/deposition
One possibility for differences in disease progression in IFNAR1 −/− versus WT animals is via changes in extracellular prion protein (PrP) levels or deposition. Total PrP levels and proteinase K-resistant PrP levels
were assessed by Western blotting using 6D11 and quantified. When Using cell isolations, we show here that Ifnb1 is expressed in microglial but not astrocytic cells, whereas the primary IFN-dependent genes were expressed in both microglia and astrocytes.
Although there have been several studies of IFN-I upregulation in CNS disease and in aging (Baruch et al., 2014; Khorooshi & Owens, 2010; Main et al., 2016; Minter et al., 2016; Wang et al., 2011) , the molecular trigger for these events has been unclear.
Here, we show clear upregulation of the DNA damage sensors p204 and cyclic GMP-AMP synthase (cGAS), which can detect DNA damage intracellularly and generate cyclic GMP-AMP (Chen, Sun, & Chen, 2016; Hartlova et al., 2015) . This can trigger IFN-I responses via interaction with the endoplasmic reticulum (ER)-associated adapter STING (Gurtler & Bowie, 2013; Ishikawa et al., 2009) . These receptors are expressed by both microglia and astrocytes and can mediate robust IFN-I responses to transfected viral DNA (Cox et al., 2015) .
Here, we show, in vivo, that Ifnb1 transcription occurs in microglia in chronic neurodegenerative disease and is STING-dependent. To our knowledge, this is the first demonstration that STING activation drives detrimental microglial IFN-I responses in chronic neurodegenerative disease. A recent study showed that the IFN-I response to traumatic brain injury to be STING-dependent (Abdullah et al., 2018) . Interestingly, STING has been also recently been shown to be activated by the antiviral drug ganciclovir and to suppress neuroinflammation in EAE (Mathur et al., 2017) . However, EAE is characterized by significant immune cell infiltration, and in that setting, IFNAR1 plays a beneficial role (Prinz et al., 2008) . By contrast, ME7 is dominated by local microglial proliferation (Gomez-Nicola, Fransen, Suzzi, & Perry, 2013) , and our data show that both STING and IFNAR1 deletions limit detrimental microglial responses. This emphasizes that the impact of IFN-I, and now that of STING, on neuroinflammatory, outcomes are dependent on the nature of inflammation driving the disease. The precise mechanism of STING activation in this model requires further research. We have used antibodies against γH2AX to show dsDNA breaks in cells of the hippocampus and thalamus in ME7
(Supplementary Information Figure S1 ), and escape of damaged dsDNA from the nucleus can result in cytoplasmic sensing by cGAS-STING. Similarly, mitochondrial DNA is a strong stimulus for STING (Carroll et al., 2016) , and mitochondrial damage is prominent in the inner and outer mitochondrial membranes in the ME7 model (Siskova et al., 2010) . Finally, phagocytosis of cell-free DNA by microglia may also lead to STING activation (Marsman, Zeerleder, & Luken, 2016) .
These possibilities require further study.
| Impact of IFNAR1-deficiency on microglial phenotype
We have previously shown major increases in phagocytic and lysosomal transcripts and increased phagocytic activity in ME7 animals (Hughes et al., 2010) , and here, we show that a large number of these transcripts are suppressed in IFNAR1 −/− mice. Initial experiments used RNA isolated from homogenates of the hippocampus and thalamus, the major regions of pathology in the ME7 model, and the patterns observed in those crude preparations were almost entirely replicated in microglial cells isolated, by FACS sorting, from these same regions. Most inflammatory transcripts were suppressed in In the APP/PS1 double transgenic model of AD, disease-associated increases in mRNA for iNOS were reversed in APP/PS1 × IFNAR1
−/− FIGURE 10 Neuropathological and neurological impact of IFNAR1 deficiency during prion disease. (a) Normal brain homogenate (NBH) and ME7 mice on WT and IFNAR1-deficient backgrounds were labeled with Sy38 (anti-synaptophysin) and anti-NeuN antibodies to assess (a) synaptic and (c) neuronal loss, respectively, and these were then quantified by density ratio analysis (b) and manual cell counting (d), respectively (n = 5 for both ME7 groups and 4 for NBH). * denotes p < 0.05 by Student's t-test. (e, f ) NBH and ME7-inoculated wild-type and IFNAR1 −/− mice were assessed weekly on the horizontal bar (e) and inverted screen (f ) tests for motor coordination and muscle strength. Significant differences between ME7 groups on the horizontal bar following Bonferroni post hoc tests after two-way repeated measures ANOVA, are denoted by *.
(b) Significant differences between ME7 groups on the inverted screen following Bonferroni post hoc tests after two-way repeated measures ANOVA, are denoted by p < 0.05, **p < 0.01, and ***p < 0.001 (n = 5 wt NBH, n = 6 IFNAR1 −/− NBH, n = 20 wt ME7, n = 15 for IFNAR1 −/− ME7). All data are expressed as mean ± SEM. (g) Survival analysis was performed on WT and IFNAR1-deficient ME7 mice using 15% body weight loss as a humane endpoint, and *** denotes a significantly increased survival time in IFNAR1 −/− mice (p < 0.0001) by Kaplan-Meier log-rank survival analysis mice, whereas increases in IL-1 and the "anti-inflammatory" transcripts for Arg1, TREM2 and TGFβ1 were further increased in the IFNAR1-deficient mice (Minter et al., 2016) . We found both Trem2 and Tgfb1 to be robustly suppressed in IFNAR1 −/− ME7 mice. Recent single-cell transcriptomic studies indicate two-stage microglial activation in murine neurodegenerative models (Keren-Shaul et al., 2017; Mathys et al., 2017) , with IFN-I expression in the later stages (Mathys et al., 2017) . Transition to the "disease-associated microglia" phenotype was found to be Trem2-dependent (Keren-Shaul et al., 2017) .
Our observation that microglia from IFNAR1 −/− ME7 mice became activated but did not upregulate Trem2 and did attain the moredamaging phagocytic phenotype might be explained by the reduction in Trem2 expression.
Conversely, Tnfa showed similar disease-associated IFNAR1-dependent induction in both APP/PS1 and ME7 models ( Figure 5 and (Minter et al., 2016) . Both Il1b and Tnfa are reported to be elevated in the MPTP model of Parkinson's disease, and IFNAR1 deficiency was also shown to reverse these, although fold-increases in these transcripts were relatively small and rather variable (Main et al., 2016) .
It is likely that impaired STAT1 signaling contributes to the changes in microglial activation observed here and STAT1 levels are known to be lower in IFNAR1 −/− mice . However, it has recently emerged that IFN-β may also signal through IFNAR1
without dimerization with IFNAR2 and without activation of the JAK-STAT pathway (de Weerd et al., 2013 ). This signaling is believed to drive a more pro-inflammatory state than canonical IFN-I signaling, 
| Phagocytic and lysosomal changes in microglia
The major pattern observed in the current transcriptional analysis was a suppression of genes associated with phagocytosis and lysosomal activity including scavenger receptors, components of the complement pathway, and NADPH oxidase and lysosomal cathepsins. There is evidence for a role for complement-mediated opsonization of synaptic elements in models of AD (Hong et al., 2016; Stevens et al., 2007) , and activation of phagocytic and lysosomal pathways is conserved across multiple neurodegenerative diseases (Holtman et al., 2015) . Recent studies of repeated systemic LPS-induced neurodegenerative changes in the substantia nigra showed a marked transcriptional shift toward increased complement and phagosome pathway activation, including the products of many of the genes we found to be IFN-dependent in the current study, such as p22phox, gp91, C3, cathepsin S, CD68, and components of the C3 receptor complex (Bodea et al., 2014) . In the repeated LPS-model, degeneration was shown to be C3-dependent, giving credence to the notion that driving excessive phagocytic activity in microglia may be detrimental to neuronal integrity. There is also direct evidence that inhibition of microglial phagocytosis limits inflammatory neuronal death in other model systems (Neher et al., 2011) . Therefore, there is evidence to support the idea that mitigating these pathways, in this case via deletion of IFNAR1, will slow degenerative processes. Niemann-Pick C mice (German et al., 2002) and like those authors, we speculate that this represents significantly higher lysosomal degradative activity in wild-type ME7 animals and that this may contribute to the neuronal and synaptic loss seen in this region. Although cathepsin D is also important for neuronal integrity (Shacka et al., 2007) , its expression appears to be preserved in surviving thalamic neurons and indeed IFNAR1 −/− mice actually show greater protection against disease-associated loss of thalamic neurons (Figure 7d ).
It may be significant that ME7-associated increases in IBA-1, cathepsin D, and CD68 expression in white matter (cc and internal capsule) were mitigated in IFNAR1 −/− mice. Recently, a deficiency in the ubiquitin specific protease 18 (usp18) was shown to specifically activate white matter microglia, and this was mediated specifically by a loss of regulation of STAT1 signaling and uncontrolled IFN-I activity (Goldmann et al., 2015) . This resulted in a loss of microglial "quiescence" in the white matter and brought about white matter damage.
The disease process in the current model clearly activates microglia in WM bundles exiting the main hippocampal and thalamic areas of pathology, and this happens relatively late in disease and is significantly mitigated in IFNAR1 −/− . The differences in WM microgliosis in WT ME7 but not IFNAR1 −/− may simply reflect a slower progression of disease to those WM areas in IFNAR1 −/− mice but a specific impact of microglial IFNAR1 −/− deletion in white matter tracts certainly merits investigation. The idea that IFN-I is a key regulator of the microglial clearance of axonal material was already apparent in earlier work in perforant path degeneration (Khorooshi & Owens, 2010) and in dorsal root axotomy (Hosmane et al., 2012) and its robust upregulation in this chronic degenerative model, with effects of IFNAR1 deletion on microglial pathways of opsonization, phagocytosis, and lysosomal activity suggest that IFN-I expression and action is a fundamental component of the microglial response to neurodegeneration.
However, unlike in the acute models described above, it also appears to contribute to chronic neurological decline. The current model indicates that phagocytic activation of microglia is detrimental to synaptic and neuronal integrity in ME7, consistent with the protective effects of limiting microglial proliferation in this model via inhibition of CSF1r (Gomez-Nicola et al., 2013) .
| Impact of IFNAR1-deficiency on disease progression
Prion disease-induced neurological impairments were manifest from about 17 weeks in wild-type ME7 animals, as previously reported, and the onset of these impairments was delayed by approximately 2 weeks in IFNAR1 −/− ME7 animals. Kaplan-Meier analysis showed that these mice also survive on average 2 weeks longer than wild-type controls (median survival 162 vs 148 days), and almost all WT animals had reached the humane endpoint before any IFNAR1 −/− mice did. In addition, synaptic loss in the VPL and NeuN-positive neuronal loss in the Po nucleus of the thalamus both showed robust degeneration as previously described Reis et al., 2015) and were not different in IFNAR1 −/− mice (Supplementary Information Figure S1 ). This is an important observation because it indicates that neither early clearance of the surgically inoculated infectious material (Beringue et al., 2000) nor early stages in disease development are affected by non-responsiveness to IFN-I. That IFNAR1-deficiency does not affect those processes but does affect later stages of disease indicates that the IFN-I response is part of a disease-associated inflammation that occurs secondary to disease but nonetheless does contribute to the rate of decline. Such longitudinal analysis has typically not been performed in other model systems in which IFNAR1 has been shown to be influential.
In stressing the importance of IFN-I influence on microglial function, it is important to emphasize two other aspects of disease.
(1) Proteinase K-resistant PrP and extracellular formic-acid resistant PrP were equivalent in histological sections of WT and IFNAR1 −/− mice, indicating that the observed changes in microglial phenotype are not secondary to changes in tissue PrP deposition. (2) ER stress, which has been reported to drive neurotoxicity in prion disease (using tg37 mice that overexpress PrP six-fold [Moreno et al., 2012] ), can occur via PKR-dependent phosphorylation of eIF2α (Vattem, Staschke, & Wek, 2001 ) and consequent translational repression. However, despite robust IFNAR1-dependent increases in PKR, we observed no changes in eIF2α phosphorylation.
Thus, IFN-I and STING are drivers of chronic neurodegeneration in prion disease. This dovetails with older studies with interferon inducers (as a proposed treatment for what was then believed to be a viral disease) showing accelerated prion disease (Allen & Cochran, 1977) . Moreover, our own prior studies showed that multiple peripheral challenges with the IFN-I inducer poly I:C produced repeated acute disease exacerbations and accelerated the progression of disease .
| CONCLUSION
Despite its well-established beneficial anti-inflammatory effects in viral infections (Isaacs & Lindenmann, 1957; Pestka, Langer, Zoon, & Samuel, 1987) and the widespread use of IFNβ as a therapy for relapsingremitting MS (Goodin et al., 2002) and protective effects of both STING and IFN-I in EAE (Mathur et al., 2017; Prinz et al., 2008) , the results of the current study show that STING-mediated IFN-I induction has multiple effects on microglial phenotype and contributes to chronic neurodegeneration. Protective effects against disease progression in the current study could not be explained by effects on eIF2α or on PrP deposition indicating that modulation of microglial activity may be key to the protective effects observed. The demonstration that IFN-I arises via STING activation establishes this pathway as a potential target in neurodegenerative disease and the observed changes in microglial phenotype expand our understanding of the impact of IFN-I on microglial function during chronic neurodegeneration. 
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